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Helium has a low density and the potential of reducing the work of breathing and improving alveolar ventilation when replacing
nitrogen in air. A Phase II, double-blind, randomised, prospective, controlled trial was undertaken to assess whether Heliox28 (72%
He/28% O2) compared with oxygen-enriched air (72% N2/28% O2) or medical air (78.9% N2/21.1% O2) could reduce dyspnoea and
improve the exercise capability of patients with primary lung cancer and dyspnoea on exertion (Borg 43). A total of 12 patients
(seven male, five female patients, age 53–78) breathed the test gases in randomised order via a facemask and inspiratory demand
valve at rest and while performing 6-min walk tests. Pulse oximetry (SaO2) was recorded continuously. Respiratory rate and
dyspnoea ratings (Borg and VAS) were taken before and immediately post-walk. Breathing Heliox28 at rest significantly increased
SaO2 compared to oxygen-enriched air (9672 cf. 9472, Po0.01). When compared to medical air, breathing Heliox28 but not
oxygen-enriched air gave a significant improvement in the exercise capability (Po0.0001), SaO2 (Po0.05) and dyspnoea scores
(VAS, Po0.05) of lung cancer patients.
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Dyspnoea is a common symptom in patients with lung
malignancies with published data indicating that the prevalence
is over 70% in patients in the terminal stages (Krech et al,
1992; Komurcu et al, 2000; Dudgeon et al, 2001a). The incidence
and severity of dyspnoea increases with the progression of
the disease, becoming very distressing to both patient and carers
(Ahmedzai, 1998; Sergysels, 1998). Inadequate palliation of their
dyspnoea has significant implications for the patient’s functioning
and quality of life, with resulting economic implications if
potentially avoidable hospital admissions or inappropriate inter-
ventions take place.
While the mechanism of breathing and the consequences of
different pathological conditions for both respiratory function and
gas exchange are well known, the genesis and pathophysiology of
dyspnoea as a symptom are much less well understood (Manning
and Schwartzstein, 1995). There is relatively little published
literature on the characterisation and management of this
symptom (compared with other cancer-related conditions).
Standard therapy for dyspnoea usually involves both pharmaco-
logical and nonpharmacological treatment; however, to date there
has been little conclusive evidence to support the efficacy of such
treatments, particularly in palliative care of patients in advanced
stages (Bruera et al 1993; Booth et al, 1996; Chen et al, 1998;
Zeppetella, 1998; Luce and Luce, 2001; Legrand, 2002,). Thus, there
is an urgent need for a treatment that will reduce this common and
distressing symptom.
Helium/oxygen gas mixtures have been used for many years
in the management of severe upper-airway obstruction associated
with tumour (Hessan et al, 1988; Tan et al, 1990), asthma
(Shuie and Gluck, 1989; Kass and Castriotta, 1995; Gluck
et al, 1990), chronic obstructive pulmonary disease (COPD)(Grape
et al, 1960; Ishikawa and Segal, 1973; Jaber et al, 2000)
and a variety of other conditions (Elleau et al, 1993; Paret
et al, 1996; Beckmann and Brueggemann, 2000; Khanlou
and Eiger, 2001). The clinical effectiveness of this respiratory
gas mixture is principally due to the lower density and
higher viscosity exhibited by helium/oxygen gas mixtures
compared to air or oxygen alone. These properties promote
a move from turbulent to more laminar flow in terminal airways
and a decreased resistance to flow (Papamoschou, 1995). In
selected patients, therefore, the use of Heliox28 gas mixtures may
reduce the work of breathing, that is, more oxygen may be
presented to the alveoli for the same ventilatory effort (DeWeese
et al, 1983).
Clinically, helium/oxygen (Heliox) gas mixture administration is
usually recommended in circumstances where a rapid decrease in
respiratory muscle effort and a reduction in partial pressure of
carbon dioxide (PaCO2) are required. This form of therapy could
well provide substantial benefit for lung cancer patients with
dyspnoea for whom ventilatory assistance would be inappropriate.
The principal objective of this Phase II study was to assess the
efficacy of Heliox28 (helium/oxygen mixture containing 72%
helium and 28% oxygen) in the palliation of dyspnoea in patients
with lung cancer. Secondary objectives centred on the relative
exercise capacity of patients breathing Heliox28 compared to
controls of medical air and oxygen-enriched air (28% oxygen in
nitrogen).
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lMETHODS
Study design
This was a single-centre, double-blind, randomised, crossover
study to assess the effect of Heliox28 (72% helium/28% oxygen),
compared to medical air (78.9% nitrogen (N2)/21.1% O2)o r
oxygen-enriched air (72% N2/28% O2) in relieving dyspnoea on
exertion. The study had Local Ethics (IRB) approval, and each
patient gave written informed consent. Patients were recruited
from lung cancer outpatient clinics after initial diagnosis and
attended the study centre for an initial screening visit and a second
visit not later than 2 weeks after the screening visit to assess the
effects of the three gas mixtures. The study was conducted
according to ICH, GCP guidelines.
Screening visit
At this visit, all consenting patients were assessed for eligibility
against the inclusion and exclusion criteria (Table 1).
Demographic data and information concerning the patient’s
lung cancer diagnosis were recorded (Table 2). Standard
blood haematology and biochemistry analysis was also performed.
Patients were asked to rate the general extent of their dyspnoea
at rest and on exertion according to both a 10cm visual
analogue scale (VAS), where 0cm was no breathlessness
and 10cm worst breathlessness, and the modified Borg scale
(Borg, 1982; Table 3). The patient’s General Practitioner and other
care workers were informed of the patient’s participation in the
study.
Test gas mixture assessment
Vital signs, sitting blood pressure, heart rate (Blood pressure
monitor, Model 711, Omron, UK), respiratory rate and tympanic
temperature (Tympanic thermometer, Model 2090, IVAC Corpora-
tion, San Diego, CA, USA) were recorded. Lung transfer factor
(Pulmolab, Morgan Medical, UK) was measured and the patient
underwent the following spirometry assessments: forced expira-
tory volume in 1s (FEV1), forced vital capacity (FVC) and peak
expiratory flow (PEF) (MicroLab spirometer, MicroMedical Ltd,
UK). Maximum inspiratory pressure (MIP) (Respiratory Muscle
Trainer RT2, DeVilbiss, Sunrise Medical UK) was measured as an
indirect assessment of inspiratory muscle strength and an
indication of respiratory muscle fatigue.
Following these basic assessments, the patient undertook a
preliminary practice 6-min walk test while breathing room air
(Butland et al, 1982) during which the patient was encouraged in a
standardised way (‘you’re doing well’, or ‘keep up the good
work’). This was undertaken to familiarise the patient with
the procedures but did not form part of the analysis of the effects
of the randomised test gas mixtures. The effects of each of
the test gas mixtures on dyspnoea on exertion were then assessed
during a three-period crossover phase. Helium will increase
the pitch of the voice; therefore, patients were instructed
not to speak while breathing the gas mixtures to avoid unblinding.
Test gas mixtures were received in random sequence via a
non-rebreathing mask and demand valve system (Sabre
Medical Division, Sabre Safety Ltd, UK) connected via a
high-pressure tubing to a portable 2l cyclinder (BC 2l/200bar,
BOC Ltd, Guildford, UK) carried by the investigator walking
alongside the patient. Gas mixtures were administered at a
rate of 8–10lmin
 1. Distance walked was noted and pulse
oximetry (SaO2) (Minolta PulseOx3ia, DeVilbiss, Sunrise Medical
UK) recorded continuously to give resting SaO2 before and after
breathing the gas mixture for 5min. The minimum SaO2 during
the 6-min walk test was also recorded.
Immediately after the 6-min walk, the patient’s MIP, body
temperature and respiratory rate were measured, and the extent of
dyspnoea during the walk test assessed (VAS and Borg scales). A
minimum 15-min rest period was given between test gas
administrations.
Table 1 Study conclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Male or female of age 418 years Pregnant or lactating women
Have a diagnosis of lung cancer
(radiologically and/or histologically)
Dyspnoea at rest (Borg score of 3
or more)
Dyspnoea on exertion (Borg score
of 3 or more)
History of psychiatric disabilities, seizures
or central nervous system disorders
Life expectancy of at least 3 months
Be willing and able to comply
with the study protocol for the
duration of the study
Serious uncontrolled intercurrent
infections
Haemoglobin o10gdl
 1
History/risk of hypercapnic respiratory
failure
Cytotoxic chemotherapy or radiation
therapy within 4 weeks of study
Participation in any other investigational
drug study
Table 2 Patient Characteristics
Range (median)
Age (years) 58–78 (72.5)
Transfer factor (mmolmin
 1kPa
 1) 2.3–8.86 (3.47)
FVC (l) 0.87–3.42 (1.94)
FEV1 (l) 0. 60–0.722 (1.26)
FEV1/FVC (%) 39–82 (72)
PEF (lmin
 1) 54–472 (185)
SaO2 at rest (%) 91–98 (94)
Dyspnoea (modified Borg)
At rest 0–1.0 (0)
On exertion 3.0–4.0 (3.0)
Pathology of lung cancer
Small cell n¼1
Non-small cell n¼11
Stage of tumour
Stage I n¼9
Stage II n¼2
Stage III n¼1
Table 3 Modified Borg scale
Score Symptoms
0 Nothing at all
0.5 Very very slight (but noticeable)
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
9 Very very severe
10 Maximal
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lStatistical analysis
Results are expressed as mean7s.e.m. ANOVA was applied to the
analysis of the three-period, six-sequence crossover design to
explore the visual analogue data with special attention to assess
potential carry-over effects. Within-patient comparisons were
carried out using paired t-test with values considered significant
at Po0.05. In addition, 95% confidence intervals (CI) are
expressed for observed differences. As this was an exploratory
study to determine the effect of Heliox28, for which no previous
data exist in lung cancer, a formal sample size calculation for
comparisons was deemed inappropriate.
RESULTS
Patients
In all, 12 patients were randomised and all completed the study. All
12 subjects (seven male and five female subjects) were Caucasian
aged 53–78 years. Height and weight ranged from 152 to 188cm
and 47.6 to 104.8kg, respectively. Transfer factor and spirometry
values are shown in Table 2, and are indicative of mild to moderate
airway obstruction. There were no clinically significant abnormal
blood laboratory values.
Walk test assessments
Assessment of dyspnoea (VAS and Borg scores) The self-assess-
ment of dyspnoea using the VAS showed that patients were
significantly less breathless following Heliox28 (40.274.8%) than
following medical air (59.375.3%) (Po0.05; 95% CI: 2.5–35.7%).
No significant differences were detected in mean VAS between
Heliox28 and oxygen-enriched air (47.075.6%) or between
oxygen-enriched air and medical air administrations. After each
walk test, modified Borg scores were 2.570.5 with Heliox28,
3.570.6 with nitrogen/oxygen and 3.770.6 with medical air. There
were no statistically significant differences between any of the Borg
score assessments (Figure 1).
Distance walked Patients walked significantly further following
the administration of Heliox28 (214.279.6m) than following the
administration of oxygen-enriched air (174.6711.2m) (Po0.05;
95% CI: 8.4–70.6m) and medical air (128.8710.3m) (Po0.0001;
95% CI: 55.7–114.9m). Although the distance walked with oxygen-
enriched air was less than with Heliox28, it was still significantly
greater than with medical air (Po0.01; 95% CI: 13.9–77.6m)
(Figure 2A).
Time spent walking Patients walked for longer, and spent less
time resting, following the administration of Heliox28 (310718s)
than following oxygen-enriched air (288721s, NS) or medical air
(235719s; Po0.01; 95% CI: 19–130s) (Figure 2B).
Oxygen saturation (SaO2) Initial SaO2 (94.970.28% Heliox28,
94.770.3% oxygen-enriched air and 94.170.3% medical air) on
breathing room air before administration of the three test gas
mixtures was not significantly different. SaO2 after breathing the
test gas mixture for 5min at rest before the walking test was
significantly higher with Heliox28 (95.870.4%) than with medical
air (92.770.4%) (Po0.0001; 95% CI: 1.9–4.2%) and oxygen-
enriched air (94.070.4%) (Po0.01; 95% CI: 0.5–2.9%). Mean
SaO2 value after 5min administration of oxygen-enriched air was
not significantly different from that of medical air. During the 6-
min walk test, the difference between the minimum SaO2 recorded
with the Heliox28 (91.770.9%) and medical air (88.771.0%) was
statistically significant (Po0.05; 95% CI: 0.1–5.8%). Although the
mean minimum SaO2 value was higher with Heliox28 than with
oxygen-enriched air (90.871.1%), this difference was not sig-
nificant (Figure 3).
Maximum inspiratory pressure (MIP) and sustained MIP area -
Following the baseline walk test breathing room air, the mean MIP
was 35.7cm H2O (range: 6–67cm H2O). The MIP following each
subsequent walk was 38.9712.2, 38.2711.8 and 36.4710.5cm
H2O (Heliox28, oxygen-enriched air and medical air, respectively).
There were no statistically significant treatment differences in MIP.
Tympanic temperature At the end of the 5-min period breathing
the test gas mixtures at rest before the walk test, mean tympanic
temperature was 36.170.1, 36.270.1 and 36.370.11C (Heliox28,
oxygen-enriched air and medical air, respectively). Following the
walk tests, there was a small but significant (Po0.05; 95% CI:
0.06–0.761C) decrease in temperature after Heliox28 compared to
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Figure 1 Dyspnoea scores recorded after 6-min walk test while
breathing helium/oxygen (72% He/28% O2), oxygen-enriched air (72%
N2/28% O2) and medical air (78.9% N2/21.1% O2). Mean7s.e.m. (n¼12)
modified Borg: ; and VAS (0–10): &;# :Po0.01 cf. medical air.
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Figure 2 Distance walked and time spent resting during 6-min walk test
while breathing test gas mixtures, helium/oxygen (72% He/28% O2),
oxygen-enriched air (72% N2/28% O2) and medical air (78.9% N2/21.1%
O2). Mean7s.e.m. (n¼12), : distance walked; &: time resting; #:
Po0.01 cf. medical air; *: Po0.05 cf. oxygen-enriched air.
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loxygen-enriched air (35.870.1, 36.270.1 and 36.170.11C, He-
liox28, oxygen-enriched air and medical air, respectively).
Respiratory rate After breathing the test gas mixture for 5min at
rest, respiratory rate was 18.570.3, 18.170.3 and 18.170.3breath-
smin
 1 (Heliox28, oxygen-enriched air and medical air, respec-
tively). Immediately following the 6-min walks, mean respiratory
rate increased to 24.270.6, 25.170.7 and 27.270.6breathsmin
 1
(Heliox28, oxygen-enriched air and medical air, respectively).
Compared to medical air, the exercise-induced increase was
significantly lower after breathing Heliox28 (Po0.005; 95% CI:
1.3–4.8) and oxygen-enriched air (Po0.05; 95% CI:  0.2–4.0).
Safety All three test gases appeared to be safe and well tolerated
in this population of 12 lung cancer patients with no severe or
serious adverse events or deaths reported during the study.
DISCUSSION
This is the first randomised controlled trial of Heliox28 in patients
with cancer and exertional dyspnoea. It is also the first study to use
Heliox28 in this population. The results showed a consistent trend
in comparisons for a therapeutic efficacy in the order of Heliox28,
oxygen-enriched air and medical air gas mixtures. Dyspnoea on
exercise, as assessed by VAS, was significantly lower with Heliox28
than with medical air. This proved to be a more sensitive measure
in the present trial than the modified Borg score, which is used
extensively in respiratory medicine studies. On average, patients
walked for longer breathing Heliox28 than either medical air or
oxygen-enriched air and also spent significantly less time resting
than with medical air. The mean SaO2 after breathing the gas at
rest for 5min and minimum SaO2 during the walk test were both
significantly higher with Heliox28 group than with oxygen-
enriched air.
Breathing helium-enriched gas mixtures can reduce core body
temperature because helium is a better conductor of heat than
nitrogen. A slight fall in tympanic temperature was noted in our
study after eleven min of continuous administration of Heliox28.
This fall was statistically significant but not of a magnitude to be
considered clinically significant.
There were no significant treatment differences in MIP or heart
rate. As with other reports of the clinical use of Heliox28 gas
mixtures (Manthous et al, 1997; Rodrigo et al, 2001), this study did
not highlight any safety concerns associated with the use of
Heliox28.
The results from this study support previous reports of the
beneficial use of Heliox28 in the treatment of obstructive lung
disease (Shuie and Gluck, 1989; Gluck et al 1990; Tan et al, 1990).
All of the patients in this study were current or ex-smokers and
their FEV1/FVC all showed varying degrees of airway obstruction
but we were unable to determine how much of their obstruction
was due to concomitant COPD or to their cancer. No correlation
was found between the degree of airway obstruction and changes
in SaO2, dyspnoea and distance walked in response to either
Heliox28 or oxygen-enriched air.
Most of the beneficial effects of the use of inspired helium can be
attributed to its physical properties of lower density and increased
viscosity, compared with nitrogen. These properties lead to
improved laminar gas flow in the bronchi, resulting in increased
oxygenation of the alveoli and decreased carbon dioxide retention.
Clinically, this has been reported in several studies as a more rapid
fall in PaCO2 with helium/oxygen mixtures than with conventional
therapy (Swidwa et al 1985; Oelberg et al, 1998; Jolliet et al, 1999;
Kass and Terregino, 1999; Jaber et al, 2000). In this present study,
blood gas analysis was not carried out and, therefore, PaCO2 values
are unknown. However, the significantly higher pulse oximetry
(SaO2) values both at rest and during exercise with Heliox28
compared to oxygen-enriched air are strongly indicative of an
increase in alveolar ventilation with Heliox28.
In some COPD patients with long-standing disease, increasing
their alveolar oxygenation with a high concentration of inspired
oxygen raises the possibility of decreased hypoxic drive and
subsequent increased carbon dioxide retention. In view of the
significant degree of obstruction in this sample of patients, the BTS
Guidelines (1998) were followed by using 28% oxygen in our
helium mixture. Although several patients entering our study
showed evidence of mild hypoxia, none could be classed as
severely hypoxic (SaO2 o90%) or would have met the British
Thoracic Society criteria for long-term oxygen therapy (SaO2
o92%) (BTS Guidelines, 1998).
When used to treat patients with respiratory distress, helium gas
mixtures are usually administered via a system of delivery that
does not allow air entrainment, thus providing the full helium/
oxygen concentration to be inspired. For practical reasons, this
study used a delivery system incorporating a mask and demand
valve. However, any effect of the delivery system could not be
quantified as the walk test breathing room air, that is without any
mask, was undertaken first to familiarise the patient to the
procedures and was not randomised within the test gas mixture
administration.
The decreased resistance to flow of helium/oxygen mixtures may
benefit subjects by decreasing the work of breathing and reducing
fatigue of respiratory muscles, during periods of increased
ventilatory requirement. Jaber et al (2000) reported a reduction
in inspiration time with helium/oxygen mixtures, indicating a
reduction in the work of breathing. The increases in tidal volume
with helium/oxygen reported by Fink et al (2003), in a lung model,
are interesting in this context and provide additional evidence for
increased ventilation for the same ventilatory effort. MIP is often
used as a measure of respiratory muscle fatigue, but in the present
study between- and within-patient variability proved too great to
demonstrate any significant differences. The marked weight loss
found in many cancer patients with progression of the disease may
also compromise ventilatory effort (Dudgeon et al, 2001b). We
found that both Heliox28 and oxygen-enriched air enabled a
reduction in the exercise-induced increase in respiratory rate in
comparison to medical air, which could prove beneficial to these
patients.
In general, studies of advanced cancer show that patients’
perception of dyspnoea bears little direct relationship to either
their SaO2 or lung function impairment, although there may be
within-patient correlation (Bruera et al, 2000; Dudgeon et al,
2001b). Results from this study would agree with this general-
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Figure 3 Pulse oximetry readings breathing room air, after breathing the
test gas mixture at rest for 5min and minimum reading during 6-min walk
test while breathing test gases: helium/oxygen (72% He/28% O2), oxygen-
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lisation as we could find no correlation between dyspnoea scores
and lung function impairment or treatment SaO2 responses.
Although there is some evidence in the respiratory literature on
the effectiveness of the appropriate use of oxygen in the short- and
long-term management of dyspnoea in patients with chronic lung
disease (Davidson et al, 1988; Swinburn et al, 1991), there is little
conclusive evidence of its benefits in patients with malignancy, in
particular those with lung cancer or metastatic thoracic disease.
Two randomised studies have investigated the effects of oxygen
on dyspnoea in resting terminally ill cancer patients. Bruera et al
(1993) found that 12 out of 14 patients, with hypoxaemic dyspnoea
at rest, consistently preferred oxygen to air; similarly, the
investigator consistently chose oxygen for the same 12 patients.
In a global rating questionnaire, patients reported ‘little’ or ‘no
benefit’ during the air phase compared with ‘moderate’ to ‘much
benefit’ during the oxygen phase.
Booth et al (1996) conducted another double-blind crossover
study to investigate whether oxygen aided the relief of dyspnoea at
rest in 38 hospice patients with advanced cancer. Unlike Bruera’s
patients, their subjects were not hypoxic at rest. Mean VAS was
significantly reduced following the administration of both air and
oxygen, with no significant difference between the two gas mixtures.
In our study, patients were comparable to those of Booth et al,
that is dyspnoeic on exertion but not hypoxaemic at rest. These
probably represent the greater majority of cancer patients with
dyspnoea. Our results indeed support those of Booth et al in that
we could find no significant difference in relieving dyspnoea with
28% oxygen compared to medical air. However, our patients and
those of Booth et al could not be classed as severely hypoxic at rest
(SaO2 o90%) in contrast to those of Bruera et al. It is likely that
the benefit from conventional oxygen therapy is greatest in those
patients whose dyspnoea is a function of their low SaO2,a si n
Bruera’s study. Significantly, while we were unable to identify a
statistical improvement with oxygen-enriched air, Heliox28
therapy caused a significant reduction in VAS dyspnoea scores
in our relatively non-hypoxic patients. The accompanying
improved alveolar oxygenation and decreased ventilatory effort
with Heliox28 could potentially benefit a much larger proportion
of cancer patients with dyspnoea, regardless of their degree of
desaturation.
The previous two cancer studies and our present one all had
small sample sizes and it is possible that lack of power failed to
show true significant effects. Using data from previous studies
(Swidwa et al, 1985; Garrod et al, 2000), power calculations would
require a group size of 22 patients to give 90% power at 5%
significance for Borg scores (Machin et al, 1997). Our own study
was designed as a Phase II trial to determine more accurately the
effect size following the three test gases in the experimental
situation so that future randomised trials can be designed with
sufficiently large samples.
The results from this small controlled, double-blinded
study suggest a promising beneficial role for Heliox28 therapy
in the palliation of dyspnoea in patients with cancer. These
positive clinic-based results generated interest in the more
long-term benefits and we invited patients on the study to partake
in a month-long home assessment. Results of this ‘real-life’
long-term monitoring will give information on functioning
and quality of life in these patients, and further define the role
of palliative gases in the treatment of patients with cancer-related
dyspnoea.
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